Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx (Nasdaq: RNXT) has announced a proposed underwritten public offering of common stock and pre-funded warrants. The company plans to use the proceeds for working capital and general corporate purposes, including the progression of its Phase III TIGeR-PaC study and the development of commercial sales and marketing activities for RenovoCath, their FDA-cleared delivery platform.
Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. The offering is being made through a shelf registration statement previously filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.
RenovoRx (NASDAQ: RNXT) presented promising pharmacokinetic (PK) data from their Phase III TIGeR-PaC clinical trial at ASCO GI 2025. The study, presented by Dr. Paula Novelli from the University of Pittsburgh Medical Center, compared intra-arterial gemcitabine (IAG) delivery using RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform versus standard intravenous treatment in locally advanced pancreatic cancer (LAPC).
The sub-study results demonstrated that RenovoRx's IAG approach via TAMP reduced systemic levels of gemcitabine compared to standard care, potentially decreasing related side effects while increasing local drug potency. The TAMP platform, utilizing the FDA-cleared RenovoCath® delivery system, is designed to precisely deliver therapy across the arterial wall near tumor sites.
RenovoRx (RNXT) announced the acceptance of three abstracts for presentation at major industry conferences: ASCO GI 2025, SIO 2025, and SSO 2025. The abstracts focus on the company's Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, presenting additional human pharmacokinetic data and pre-clinical results.
The presentations will highlight RenovoRx's novel approach using their FDA-cleared RenovoCath® delivery platform, which is designed to deliver targeted oncology therapies directly to tumor sites while potentially reducing toxicity compared to systemic treatments. The company's ongoing Phase III TIGeR-PaC clinical trial is evaluating their first product candidate, combining RenovoCath with gemcitabine chemotherapy. RenovoRx expects to complete both patient enrollment and the second interim analysis for TIGeR-PaC by the end of H1 2025.
RenovoRx continues to grow its intellectual property (IP) portfolio, boasting 18 issued patents and 13 pending patents, as it advances commercialization and clinical trials in 2025.
The company recently published a new international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which targets and delivers treatments directly to specific tissues using micro-vessels.
RenovoRx holds 8 issued and 6 pending U.S. patents and 10 issued and 7 pending patents outside the U.S., including its 2024 international application.
The TAMP technique aims to deliver therapies precisely to tumor sites, potentially reducing toxicities compared to systemic intravenous treatments.
RenovoRx's Phase III TIGeR-PaC clinical trial, evaluating its first product candidate using the FDA-cleared RenovoCath device, is expected to complete patient enrollment and the second interim analysis by mid-2025. The company also received its first purchase orders for the RenovoCath device.
RenovoRx (RNXT) announces the initiation of patient enrollment at SCRI Oncology Partners in Nashville for its pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC). The study evaluates the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, comparing intra-arterial gemcitabine delivery via RenovoCath against standard intravenous chemotherapy.
Dr. Meredith Pelster, Associate Director for GI Research at Sarah Cannon Research Institute (SCRI), has been appointed as Principal Investigator. The company expects to complete enrollment in the first half of 2025. SCRI Oncology Partners, part of a network reaching one in five cancer patients across 250+ locations in 24 U.S. states, joins other clinical sites participating in the study.
RenovoRx (Nasdaq: RNXT) has announced an upcoming investor fireside chat scheduled for Tuesday, December 17, 2024, at 4:30 p.m. ET. CEO Shaun Bagai will discuss the company's 2024 achievements and 2025 outlook, focusing on two key areas:
1. The commercialization strategy for the RenovoCath delivery system, including insights from newly appointed Commercial Advisor Richard Stark
2. Updates on the pivotal Phase III TIGeR-PaC clinical trial, which evaluates their proprietary TAMP™ therapy platform for locally advanced pancreatic cancer treatment. The trial combines their RenovoCath delivery system with gemcitabine chemotherapy.
Important 2025 milestones include the anticipated second interim data readout and completion of patient enrollment in the TIGeR-PaC study. The event will include a Q&A session, and a recording will be available on RenovoRx's Investor Relations website.
RenovoRx (NASDAQ: RNXT) has received its first purchase orders for its FDA-cleared RenovoCath® delivery system, with over ten medical institutions initiating the purchase process nationwide. The company estimates an initial target market size of several hundred million dollars in annual sales for RenovoCath, which is powered by their patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.
The device has been successfully used in over 500 clinical trial procedures. RenovoRx is pursuing a direct-to-market commercialization strategy and has expanded its relationship with manufacturing partner Medical Murray to increase production. The company expects to complete patient enrollment and the next interim analysis of its Phase III TIGeR-PaC clinical trial by the end of H1 2025.
RenovoRx (RNXT) announces that Northwell Health Cancer Institute (NHCI) has joined its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoRx's TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, comparing intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath system to standard intravenous chemotherapy. NHCI joins other U.S. clinical sites in the study, which aims to complete enrollment in the first half of 2025.
RenovoRx reported Q3 2024 financial results with $9.6 million in cash as of September 30, sufficient to fund operations through next interim analysis of its Phase III TIGeR-PaC clinical trial and RenovoCath commercialization efforts. The company reported a net loss of $2.5 million, with R&D expenses at $1.7 million and G&A expenses at $1.2 million. RenovoCath, their FDA-cleared delivery system, is advancing towards commercialization with increased production and potential revenue generation in 2025. The Phase III trial for locally advanced pancreatic cancer is progressing towards completion of patient enrollment, expected in first half of 2025.
RenovoRx (Nasdaq: RNXT) announces increased production of its FDA-cleared RenovoCath® delivery system due to high demand from oncologists and interventional radiologists. The company has expanded its relationship with manufacturing partner Medical Murray, issuing a warrant for up to 709,500 shares of RenovoRx common stock as performance incentives. RenovoRx remains committed to its Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), using the TAMP™ therapy platform.
The company is exploring commercial opportunities for RenovoCath as a standalone device, with plans to launch during 2025. RenovoRx has promoted Robert Strasser to Vice President of R&D and Operations to support these efforts. The company maintains sufficient cash to fund both the next interim read-out on TIGeR-PaC and RenovoCath go-to-market activities.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
